0001140361-15-015897.txt : 20150420 0001140361-15-015897.hdr.sgml : 20150420 20150420191825 ACCESSION NUMBER: 0001140361-15-015897 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150417 FILED AS OF DATE: 20150420 DATE AS OF CHANGE: 20150420 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc CENTRAL INDEX KEY: 0001302573 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383572512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-995-8200 MAIL ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gurney Austin CENTRAL INDEX KEY: 0001553353 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35993 FILM NUMBER: 15781601 MAIL ADDRESS: STREET 1: C/O ONCOMED PHARMACEUTICALS, INC. STREET 2: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc1.xml FORM 4 X0306 4 2015-04-17 0 0001302573 OncoMed Pharmaceuticals Inc OMED 0001553353 Gurney Austin C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 0 1 0 0 See Remarks Common Stock 2015-04-17 4 S 0 3850 25.4732 D 67569 D Common Stock 2015-04-17 4 S 0 150 26.5167 D 67419 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 16, 2014. This transaction was executed in multiple trades in prices ranging from $25.22 to $26.02, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. This transaction was executed in multiple trades in prices ranging from $26.39 to $26.77, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Senior Vice President, Molecular and Cellular Biology /s/ Alicia J. Hager, Attorney-in-Fact for Austin Gurney 2015-04-20